PO-1877: Survival and dosimetric parameters in stage III NSCLC patients undergoing radical chemoradiotherapy. (November 2020) - Remmerts De Vries, I.; Ronden, M.; De Haan, P.; Spoelstra, F.; Haasbeek, N.; Dahele, M.; Bahce, I.; Senan, S.; Verbakel, W.